4.8 Review

Irritable Bowel Syndrome

Journal

NEW ENGLAND JOURNAL OF MEDICINE
Volume 376, Issue 26, Pages 2566-2578

Publisher

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMra1607547

Keywords

-

Funding

  1. GE Healthcare
  2. Almirall
  3. Ironwood
  4. Covidien
  5. Salix
  6. Takeda
  7. Rome Foundation
  8. GI Therapies
  9. Prometheus
  10. Abbott
  11. Janssen
  12. Pfizer
  13. Yuhan
  14. CJ Healthcare
  15. Ardelyx
  16. Forest Laboratories
  17. Furiex
  18. Synergy
  19. GI Care
  20. Outpost Medicine
  21. Samsung Bioepis
  22. Allergan
  23. Napo Pharmaceuticals
  24. Commonwealth Laboratories
  25. Adelphi Values
  26. Mayo Clinic for questionnaires on bowel disease and dysphagia

Ask authors/readers for more resources

The irritable bowel syndrome (IBS) is a chronic and sometimes disabling functional bowel disorder.(1,2) Traditionally, this functional diagnostic label has been applied when no obvious structural or biochemical abnormalities are found, but emerging evidence suggests that distinct pathophysiological disturbances may account for the symptoms and that IBS is unlikely to be one disease or merely a psychiatric (somatosensory) disorder.(2) The Rome IV criteria, 1 derived from a consensus process by a multinational group of experts in functional gastrointestinal disorders, constitute the current standard for diagnosing IBS. According to these criteria, IBS is diagnosed on the basis of recurrent abdominal pain related to defecation or in association with a change in stool frequency or form (Table 1). Bloating is a common accompanying symptom. Symptoms must be chronic, occurring at least once per week, on average, in the previous 3 months, with a duration of at least 6 months. IBS negatively affects quality of life and work productivity. It has been estimated that patients would give up 10 to 15 years of life expectancy for an instant cure of the disease.(3) The prevalence of IBS in the United States is between 7% and 16%, and the condition is most common in women and young people.(4) Direct costs associated with IBS in the United States have been estimated, conservatively, at more than $1 billion.(5) Thus, diagnosing IBS accurately, minimizing invasive investigations, and recommending effective treatment have an important role in efforts to reduce the societal and economic effects of the disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available